￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Oncology

Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Efficacy and safety of lorlatinib in the treatment of newly diagnosed ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Xalkori (crizotinib) can be used for ALK-positive locally advanced or metastatic non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Efficacy and safety of Xacori in the treatment of ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
How long will it take for patients with lung cancer to develop resistance to Xalkori (crizotinib)?

2025-10-19 11:44:20

Check Details
Xalkori (crizotinib) has significant anti-cancer effects on ROS1-rearranged advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Study of Crizotinib (Xalkori) in Patients with EGFR Mutated Non-Small Cell Lung Cancer

2025-10-19 11:44:20

Check Details
FDA Grants Xalkori (Crizotinib) Breakthrough Drug Designation

2025-10-19 11:44:20

Check Details
Has the lung cancer targeted drug Xalkore (crizotinib) been included in the national medical insurance in China?

2025-10-19 11:44:20

Check Details
Contraindications and precautions for patients with lung cancer taking Xalkore (crizotinib)

2025-10-19 11:44:20

Check Details
Effect of Lorlatinib as first-line treatment for advanced ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
How should patients with lung cancer use Xalkori (crizotinib) correctly?

2025-10-19 11:44:20

Check Details
How much will a box of the targeted drug Xalkori (crizotinib) cost after it is included in medical insurance in 2021?

2025-10-19 11:44:20

Check Details
Category
相关知识